Guest Current Subscriptions | Open Access Plus | Free Content | About | Sign in | New Users: Sign up | Mark List  
  Inflammation & Allergy-Drug Targets (Formerly Current Drug Targets - Inflammation & Allergy)

Volume 10 Issue 3
ISSN: 1871-5281

   All Titles

NF-κB in Type 1 Diabetes
pp.208-217 (10) Authors: Yuxing Zhao, Balasubramanian Krishnamurthy, Zia U.A. Mollah, Thomas W.H. Kay, Helen E. Thomas

Type 1 diabetes is an autoimmune disease in which pancreatic beta cells are destroyed by autoreactive T cells. It is a common pediatric disease with increasing incidence. Islet transplantation may be a therapeutic option, however, the current limitations of this procedure mean that for most sufferers of type 1 diabetes there is no cure. The transcription factor NF-κB has been widely studied for its role in development of type 1 diabetes. Recent data have shown that NF-κB is required for activation of autoreactive T cells, and its hyperactivity in monocytes and dendritic cells results in altered cytokine secretion and antigen presentation, which ultimately contributes to the initiation of type 1 diabetes. NF-κB is also activated by a number of proinflammatory cytokines to regulate both the survival and death of beta cells. The critical role of NF-κB in type 1 diabetes renders it a promising pharmaceutical target in the intervention of this disease and further understanding of the NF- κB pathway will have an important implication on the development of novel and safe therapeutic strategies.

Keywords: Type 1 diabetes, NF-κB, pancreatic beta cells, cytokine secretion, Islet transplantation, beta-cell destruction, insulitis, p65/RelA, RelB, p100/NF-B1, p105/NF-B2
Affiliation: St Vincent's Institute, 41 Victoria Parade, Fitzroy, Victoria, 3065, Melbourne, Australia.

  Key: New Content Free Content Open Access Plus Subscribed Content

Bentham Science Publishers

  Copyright © 1994 - 2014   Bentham Science Publishers